BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 2445897)

  • 1. Maternal serum alpha-fetoprotein screening: benefits, risks, and costs.
    Campbell TL
    J Fam Pract; 1987 Nov; 25(5):461-7. PubMed ID: 2445897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-fetoprotein.
    Drugan A; Dvorin E; Obrien JE; Johnson MP; Evans MI
    Curr Opin Obstet Gynecol; 1991 Apr; 3(2):230-4. PubMed ID: 1717020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down's syndrome: current screening techniques.
    White RS
    South Med J; 1989 Dec; 82(12):1483-6. PubMed ID: 2480649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal serum alpha-fetoprotein screening for neural tube defects.
    Macri JN; Weiss RR
    Obstet Gynecol; 1982 May; 59(5):633-9. PubMed ID: 6175932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prenatal diagnosis. Review, personal and prospective studies].
    Engel E; Empson J; DeLozier D; McGee B; da Costa Woodson E; Engel-de Montmollin M; Carter T; Lorber C; Cassidy SB; Millis J; Heller RM; Boehm F; Vanhooydonk J
    Schweiz Med Wochenschr; 1979 Jul; 109(27):998-1010. PubMed ID: 88763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on key techniques and intervention in reducing birth defects].
    Zhu BS; Su J; Lu XH; He J; Zhu S; Jiao CX; Zhang JM; Tang XH; Tao Y; Lin KP; Chen H; Li SY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Sep; 46(9):658-63. PubMed ID: 22176989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal serum screening for neural tube defects and fetal chromosome abnormalities.
    Rose NC; Mennuti MT
    West J Med; 1993 Sep; 159(3):312-7. PubMed ID: 7694429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal diagnosis of neural tube defects. IV. Maternal serum alpha-fetoprotein screening.
    Milunsky A; Alpert E; Neff RK; Frigoletto FD
    Obstet Gynecol; 1980 Jan; 55(1):60-6. PubMed ID: 6153240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural tube defects/alpha-fetoprotein/Down's syndrome screening.
    Aitken DA; Crossley JA
    Curr Opin Obstet Gynecol; 1997 Apr; 9(2):113-20. PubMed ID: 9204233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF; Gottvall T
    Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MULTISCAN--a Scandinavian multicenter second trimester obstetric ultrasound and serum screening study.
    Jørgensen FS; Valentin L; Salvesen KA; Jørgensen C; Jensen FR; Bang J; Eik-Nes SH; Madsen M; Marsal K; Persson PH; Philip J; Bogstad JW; Nørgaard-Pedersen B
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):501-10. PubMed ID: 10376859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Maternal serum screening for Down syndrome and neural tube defects].
    van Rijn M; Christiaens GC; van der Schouw YT; Hagenaars AM; de Pater JM; Visser GH
    Ned Tijdschr Geneeskd; 1998 Feb; 142(8):409-15. PubMed ID: 9562776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of accurate gestational age estimation in screening for fetal neural tube defects using maternal serum alpha-fetoprotein levels.
    Kirkpatrick A; Cohen M; Prescott GH; Jones OW; Matson M; Wepsic HT
    UCLA Forum Med Sci; 1978; 20():199-205. PubMed ID: 80862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Fetoprotein screening.
    Burton BK
    Adv Pediatr; 1986; 33():181-96. PubMed ID: 2432763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects.
    Jaques AM; Collins VR; Haynes K; Sheffield LJ; Francis I; Forbes R; Halliday JL
    J Med Screen; 2006; 13(1):8-13. PubMed ID: 16569299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal diagnosis using the triple test.
    Palka G; Guanciali Franchi P; Papponetti M; Marcuccitti J; Morizio E; Calabrese G; Stuppia L; Di Ilio C
    Minerva Ginecol; 1998 Oct; 50(10):411-5. PubMed ID: 9866951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.